Prostate Cancer Combo Pill, Multiple Myeloma BiTE, Geographic Atrophy, POLARx for AFib

New FDA Approvals

Indhold leveret af Emma Nichols, PhD and Emma Hitt Nichols. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Emma Nichols, PhD and Emma Hitt Nichols eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

1y ago 8:21

MP4•Episode hjem

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on July 29, 2024 20:37 (3M ago)

What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Check out our free downloads at nascentmc.com:

See the full write ups for today's episodes at nascentmc.com/podcast

In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from August 7, 2023 – August 11, 2023. Please check back every Monday morning so that you can stay up to date.

Here are the highlights:

· The FDA has approved Akeega, a combination of niraparib (PARP inhibitor) and abiraterone acetate (anti-androgen), as the first orally administered treatment for BRCA-positive metastatic castration-resistant prostate cancer. The approval was based on the MAGNITUDE study showing improved progression-free survival with the addition of niraparib.

· Talvey (talquetamab-tgvs), a bispecific T-cell engaging antibody, has received accelerated approval for patients with relapsed or refractory multiple myeloma who have undergone multiple previous therapies.

· Izervay (avacincaptad pegol intravitreal solution), a complement C5 inhibitor, has gained FDA approval for use in geographic atrophy related to age-related macular degeneration, and showed a significant reduction in disease progression.

· Boston Scientific's POLARx Cryoablation System has been approved for treating paroxysmal atrial fibrillation, demonstrating effectiveness in reducing paroxysmal atrial arrhythmias in the FROZEN-AF IDE clinical trial.

The full writeups are available here: https://nascentmc.com/podcast/

Intro and outro music

Garden Of Love by Pk jazz Collective

60 episoder

#Fitness #Podcasting Education #Medicine #Emma Nichols, PhD #Emma Hitt Nichols